• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Journal articles
    • View Item
    • Home
    • Griffith Research Online
    • Journal articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Cytokine patterns after therapy with Avonex®, Rebif®, Betaferon® and CinnoVex™ in relapsing–remitting multiple sclerosis in Iranian patients

    Thumbnail
    View/Open
    63979_1.pdf (88.67Kb)
    Author(s)
    Arababadi, Mohammad Kazemi
    Mosavi, Reza
    Khorramdelazad, Hossein
    Yaghini, Narges
    Zarandi, Ebrahim Rezazadeh
    Araste, Majid
    Pourali, Reza
    Nekhei, Zohre
    Kennedy, Derek
    Griffith University Author(s)
    Kennedy, Derek D.
    Year published
    2010
    Metadata
    Show full item record
    Abstract
    Background and aim: Several lines of evidence exist which suggest that changes in the expression of circulating cytokines are linked to the development or reoccurrence of multiple sclerosis (MS). This project aimed to evaluate the serum levels of relevant cytokines after therapy with IFN-? formulations in MS patients. Material and methods: In this study, blood samples were collected from 70 MS patients undergoing four different types of IFN-? formulation treatment and 100 healthy controls. After 24 months of treatment the serum levels of IL-17A, IL-12 and IFN-g and IL-10 in patients and healthy controls were analyzed by ...
    View more >
    Background and aim: Several lines of evidence exist which suggest that changes in the expression of circulating cytokines are linked to the development or reoccurrence of multiple sclerosis (MS). This project aimed to evaluate the serum levels of relevant cytokines after therapy with IFN-? formulations in MS patients. Material and methods: In this study, blood samples were collected from 70 MS patients undergoing four different types of IFN-? formulation treatment and 100 healthy controls. After 24 months of treatment the serum levels of IL-17A, IL-12 and IFN-g and IL-10 in patients and healthy controls were analyzed by ELISA. Finding: Our results showed that serum levels of IL-17A were significantly higher in patients treated with Cinnovex and Anovex when compared to healthy controls. Serum levels of IL-10 were significantly decreased after therapy with Cinnovex, whereas serum levels of IFN-? were elevated. No difference in serum levels of IL-12 were detected in patients and controls. Conclusion: Results of our study suggest that Cinnovex and Anovex modulate the immune system less than Rebif and Betaferon in MS patients and that an elevated dosage/regime of Cinnovex and Anovex may be required for better regulation of the immune system in MS patients.
    View less >
    Journal Title
    Biomarkers in Medicine
    Volume
    4
    Issue
    5
    DOI
    https://doi.org/10.2217/BMM.10.81
    Copyright Statement
    © 2010 Future Medicine Ltd. This is the author-manuscript version of this paper. Reproduced in accordance with the copyright policy of the publisher. Please refer to the journal website for access to the definitive, published version.
    Subject
    Medical Genetics (excl. Cancer Genetics)
    Medicinal and Biomolecular Chemistry
    Medical Biochemistry and Metabolomics
    Clinical Sciences
    Publication URI
    http://hdl.handle.net/10072/34904
    Collection
    • Journal articles

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander